Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis

Table 1

Characteristics of the included studies.

Author; (year)	Interventions	Group	Country	Age (y)	Baseline HBV DNA level (log10 IU/mL)	Baseline ALT level (U/L)	HBeAg+ (%)	Study design
Hann et al. [15]; (2008)	TDF (NA); ADV (NA)	TDF (44); ADV (65)	USA	46 (11)	6.4 (1.6)	91 (161)	78	nRCT
Ong et al. [16]; (2011)	TDF (NA); ETV (NA)	TDF (18); ETV (11); LAM/ADV (77)	Hong Kong, China			89 (44–210)	50	nRCT
Yang et al. [17]; (2015)	TDF; LAM/ADV^#	TDF (28); LAM/ADV (31)	China				88.14	RCT
Maklad et al. [18]; (2014)	LAM/ADV^# ETV^&	LAM/ADV (25); ETV (13)	Egypt				41.4	nRCT
Ze et al. [19]; (2014)	LAM/ADV^# ETV^&	LAM/ADV (36); ETV (24)	Korea				91	nRCT
Chung et al. [20]; (2011)	LAM/ADV^# ETV^&	LAM/ADV (52); ETV (44)	Korea				63.45	nRCT
Ryu et al. [21]; (2010)	LAM/ADV^# ETV^&	LAM/ADV (47); ETV (45)	Korea	44 (21–64)	7.36 (5.31–9.48)	122 (22–887)	88.15	RCT
Kim et al. [22]; (2010)	LAM/ADV^# ADV^@; ETV^&	LAM/ADV (36); ADV (44); ETV (24)	Korea				69.3	nRCT
Wang et al. [23]; (2014)	LAM/ADV^# ADV^@	LAM/ADV (48); ADV (52)	China				84.05	nRCT

CHB patients with LAM-R treated with tenofovir disoproxil fumarate (TDF), lamivudine plus adefovir (LAM/ADV), entecavir (ETV), or adefovir (ADV), respectively.
TDF: patients treated with 300 g/d TDF; LAM/ADV^#: patients treated with 100 g/d LAM and 10 mg/d ADV; ETV^&: patients treated with 1 mg/d ETV; ADV^@: patients treated with 10 mg/d ADV; NA: data not available.